Trademark: 79301540
Word
NORTHWAY GENE THERAPY
Status Date
Tuesday, September 27, 2022
Registration Number
6854457
Registration Date
Tuesday, September 27, 2022
Filing Date
Wednesday, November 18, 2020
Published for Opposition
Tuesday, December 14, 2021
5 Pharmaceutical preparations, namely, for the treatment of oncological, cardiovascular, respiratory, inflammatory, autoimmune and degenerative diseases and disorders, rheumatoid arthritis, multiple sclerosis, allergies and COVID-19; drugs for medical purposes, namely, pharmaceutical preparations for the treatment of oncological, cardiovascular, respiratory, inflammatory, autoimmune and degenerative diseases and disorders, rheumatoid arthritis, multiple sclerosis, allergies and COVID-19; biological preparations for medical purposes, namely, for the treatment of oncological, cardiovascular, respiratory, inflammatory, autoimmune and degenerative diseases and disorders, rheumatoid arthritis, multiple sclerosis, allergies and COVID-19; biological tissue cultures for medical purposes, namely, for the treatment of oncological, cardiovascular, respiratory, inflammatory, autoimmune and degenerative diseases and disorders, rheumatoid arthritis, multiple sclerosis, allergies and COVID-19; albuminous preparations for medical purposes, namely, albumin dietary supplements; chemical preparations for medical purposes, namely, for the treatment of oncological, cardiovascular, respiratory, inflammatory, autoimmune and degenerative diseases and disorders, rheumatoid arthritis, multiple sclerosis, allergies and COVID-19
42 Scientific and technological services and research and design relating thereto, namely, research and design in the field of products and processes development of biotechnology products and processes; bacteriological research; biological research; chemistry services in the nature of product development and quality control of biotechnology products; chemical research; conducting clinical trials for others; scientific research; medical research; scientific laboratory services; technical research in the field of pharmaceutical studies; technological consultancy in the field of development of manufacturing processes for biotechnology products
The mark consists of the wording "NORTHWAY GENE THERAPY" with the "O" in NORTHWAY being represented by the design of a DNA Helix in dark blue and orange, the rest of the wording "NORTHWAY" in dark blue, and the wording "GENE THERAPY" below in orange. The color white represents background and/or transparent areas and is not claimed as a feature of the mark.
The color(s) dark blue and orange is/are claimed as a feature of the mark.
"GENE THERAPY"
Feb 7, 2023
Final Decision Transaction Processed By Ib
Jan 18, 2023
Final Disposition Notice Sent To Ib
Jan 18, 2023
Final Disposition Processed
Dec 27, 2022
Final Disposition Notice Created, To Be Sent To Ib
Sep 27, 2022
Notice Of Registration Confirmation Emailed
Sep 27, 2022
Registered-Principal Register
Aug 24, 2022
Ttab Release Case To Trademarks
Aug 24, 2022
Opposition Terminated No. 999999
Aug 24, 2022
Opposition Dismissed No. 999999
Jul 4, 2022
Notification Of Possible Opposition - Processed By Ib
Jun 13, 2022
Notification Of Possible Opposition Sent To Ib
Jun 8, 2022
Notification Of Possible Opposition Created, To Be Sent To Ib
Feb 6, 2022
Refusal Processed By Ib
Jan 20, 2022
Opposition Instituted No. 999999
Jan 11, 2022
Opposition Papers Received At Ttab
Jan 12, 2022
Opposition Notice (Ib Refusal) Sent To Ib
Jan 12, 2022
Opposition Notice (Ib Refusal) Created
Dec 19, 2021
Notification Processed By Ib
Dec 14, 2021
Official Gazette Publication Confirmation E-Mailed
Dec 14, 2021
Published For Opposition
Nov 26, 2021
Notification Of Possible Opposition Sent To Ib
Nov 24, 2021
Notice Of Start Of Opposition Period Created, To Be Sent To Ib
Nov 24, 2021
Notification Of Notice Of Publication E-Mailed
Nov 8, 2021
Approved For Pub - Principal Register
Nov 8, 2021
Examiner's Amendment Entered
Nov 8, 2021
Notification Of Examiners Amendment E-Mailed
Nov 8, 2021
Examiners Amendment E-Mailed
Nov 8, 2021
Examiners Amendment -Written
Oct 22, 2021
Applicant/Correspondence Changes (Non-Responsive) Entered
Oct 22, 2021
Teas Change Of Correspondence Received
Oct 22, 2021
Teas Change Of Domestic Representatives Address
Oct 22, 2021
Attorney/Dom.Rep.Revoked And/Or Appointed
Oct 22, 2021
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Oct 22, 2021
Teas Change Of Owner Address Received
Oct 22, 2021
Teas/Email Correspondence Entered
Oct 22, 2021
Correspondence Received In Law Office
Oct 22, 2021
Teas Response To Office Action Received
Jul 16, 2021
New Representative At Ib Received
May 30, 2021
Refusal Processed By Ib
May 13, 2021
Non-Final Action Mailed - Refusal Sent To Ib
May 13, 2021
Refusal Processed By Mpu
May 11, 2021
Non-Final Action (Ib Refusal) Prepared For Review
May 10, 2021
Non-Final Action Written
Apr 30, 2021
Assigned To Examiner
Jan 12, 2021
Application Filing Receipt Mailed
Jan 8, 2021
New Application Office Supplied Data Entered
Jan 7, 2021
Sn Assigned For Sect 66a Appl From Ib
Trademark Alertz updated from USPTO on 2030-01-24
